WHAT IS CLAIMED IS:

1. A pharmaceutical composition for use in the treatment of ~~treating~~ a cancer, the pharmaceutical composition comprising:

a therapeutically effective amount of a mixture of triterpenoids that comprises:

10 to 30% (wt%) of ganoderic acid S (GAS),

20 to 75% (wt%) of ganoderic acid T (GAT),

0.5 to 20% (wt%) of ganoderic acid Me (GAMe), and ganoderic acid R (GAR), and

0.5 to 20% (wt%) of ganodermic acid S (GMAS); and

a pharmaceutically acceptable excipient.

~~2. The pharmaceutical composition of claim 1, wherein the amount of GMAS is about 0.5 to 20% by weight of that of the triterpenoid.~~

~~3. The pharmaceutical composition of claim 1, wherein the amount of GAMe and GAR is about 0.5 to 20% by weight of that of the triterpenoid.~~

~~4. The pharmaceutical composition of claim 1, wherein the amount of GAT is about 20 to 75% by weight of that of the triterpenoid.~~

~~5. The pharmaceutical composition of claim 1, wherein the amount of GAS is about 10 to 30% of that of the triterpenoid.~~

~~6.~~2. The pharmaceutical composition of claim 1, wherein the cancer is any of colon cancer, hepatic cancer, breast cancer, lung cancer or leukemia.

~~7.~~3. The pharmaceutical composition of claim 2~~6~~, wherein the lung cancer is resistant to gefitinib.

~~8.~~4. Use of the pharmaceutical composition of claim 1 in the manufacture of a medicament for ~~A method of~~ treating a cancer in a subject ~~comprising administering to the subject an effective amount of the pharmaceutical composition of claim 1~~, wherein the cancer is any of colon cancer, hepatic cancer, breast cancer, lung cancer or leukemia.

~~9. The method of claim 8, wherein the amount of GMAS is about 0.5 to 20% by weight of that of the triterpenoid.~~

~~10. The method of claim 8, wherein the amount of GAMe and GAR is about 0.5 to 20% by weight of that of the triterpenoid.~~

~~11. The method of claim 8, wherein the amount of GAT is about 20 to 75% by weight of that of the triterpenoid.~~

~~12. The method of claim 8, wherein the amount of GAS is about 10 to 30% by weight of that of the triterpenoid.~~

~~13.~~5. The ~~method~~ use of claim ~~4~~8, wherein the lung cancer is resistant to gefitinib.

~~14.~~6. The ~~method~~ use of claim ~~4~~8, wherein the subject is a human.

WHAT IS CLAIMED IS:

1. A pharmaceutical composition for use in the treatment of a cancer, the pharmaceutical composition comprising:

a therapeutically effective amount of a mixture of triterpenoids that comprises:

10 to 30% (wt%) of ganoderic acid S (GAS),

20 to 75% (wt%) of ganoderic acid T (GAT),

0.5 to 20% (wt%) of ganoderic acid Me (GAMe) and ganoderic acid R (GAR), and

0.5 to 20% (wt%) of ganodermic acid S (GMAS); and

a pharmaceutically acceptable excipient.

2. The pharmaceutical composition of claim 1, wherein the cancer is any of colon cancer, hepatic cancer, breast cancer, lung cancer or leukemia.

3. The pharmaceutical composition of claim 2, wherein the lung cancer is resistant to gefitinib.

4. Use of the pharmaceutical composition of claim 1 in the manufacture of a medicament for treating a cancer in a subject, wherein the cancer is any of colon cancer, hepatic cancer, breast cancer, lung cancer or leukemia.

5. The use of claim 4, wherein the lung cancer is resistant to gefitinib.

6. The use of claim 4, wherein the subject is a human.